GLP-1 maintenance dosing: what 'fine' actually means clinically

What did @alexusdevon actually say?

She's describing a real experience, not a clinical protocol. At her current dose of 1.7 (presumably semaglutide), she says she's stopped losing weight but isn't gaining either. Her takeaway: "you will reach a weight plateau with one of the doses because it's weight maintenance." She's suggesting this plateau is normal, expected, and even useful as a stopping point if you're happy with your current weight.

This is personal testimony, not medical advice, and she frames it that way. She's responding to a question about whether weight plateaus can be prevented, and her honest answer is essentially: no, and that's kind of the point. That's a more nuanced position than most GLP-1 TikToks take, and it's worth examining carefully against the actual evidence.

Does the science back this up?

Mostly, yes. Weight plateaus on GLP-1 receptor agonists are well-documented and physiologically expected. They are not a failure of the drug. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that semaglutide 2.4 mg produced significant weight loss that largely plateaued around week 60-68, after which participants maintained rather than continued losing. This pattern held across the STEP program.

The mechanism is not mysterious. GLP-1 agonists reduce appetite and slow gastric emptying, but the body adapts. Energy expenditure adjusts downward as weight drops, and at some point the drug's appetite-suppressing effect reaches equilibrium with the body's compensatory hunger signals. This is called metabolic adaptation, and it happens with essentially every weight loss intervention, pharmaceutical or otherwise. The plateau is the body finding a new set point under drug influence, not the drug failing.

Where the science gets more complicated is the claim that staying at a lower maintenance dose will hold your weight stable long-term. That's less clearly supported than she implies.

What did they get wrong (or right)?

She got the core observation right: plateaus happen, they're normal, and they can function as a de facto maintenance phase. That's accurate and often under-communicated in GLP-1 content online.

Where she oversimplifies is the idea that staying at a lower dose indefinitely will keep weight stable. The evidence suggests this is dose-dependent and not guaranteed. Davies et al. (2021, Lancet) showed that discontinuing semaglutide led to substantial weight regain within a year, and lower doses generally produce less weight loss and potentially less stable maintenance than the approved therapeutic doses. "Staying at that dose" sounds tidy, but the relationship between dose, plateau, and long-term maintenance is not that clean in the literature.

She also doesn't mention that some people never plateau on a given dose and continue losing, while others plateau early and never progress. The plateau experience is real but variable, and presenting it as universal and predictable slightly overstates what we know.

What should you actually know?

Weight plateaus on GLP-1 medications are not a sign something went wrong. They reflect normal metabolic adaptation. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) with tirzepatide showed similar plateau patterns, with most weight loss occurring in the first 36 weeks and flattening thereafter at higher doses.

What matters clinically is what happens next. Research consistently shows that stopping GLP-1 therapy, even after a successful plateau, typically results in significant weight regain. Rubino et al. (2021, JAMA) found participants regained about two-thirds of their lost weight within a year of stopping semaglutide. This is not mentioned in the video, and it's the part that most affects long-term decision-making about dose and duration.

If you're at a dose that's holding your weight stable and you're comfortable there, that may be a reasonable place to be, but that decision should involve your prescriber, not a TikTok comment section. The idea that you can simply pick your plateau and park there permanently is appealing but not well supported by the evidence for most people.